Title:
DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2017/146236
Kind Code:
A1
Abstract:
The present invention addresses the problem of discovering and providing an effective cancer therapy by means of a drug. Provided is a drug for cancer therapy characterized by administering a combination between: a compound represented by a general formula (I) (wherein, all symbols are as described in the description), a salt thereof, a solvate thereof, an N-oxide thereof, or an Axl inhibitor as a prodrug of those; and an immune checkpoint inhibitor (e.g., anti-PD-1 antibody, etc.). The combination according to the present invention exerts a strong anti-tumor effect, and thereby is useful in cancer therapy.
Inventors:
TANAKA KOUHEI (JP)
YASUHIRO TOMOKO (JP)
YASUHIRO TOMOKO (JP)
Application Number:
PCT/JP2017/007219
Publication Date:
August 31, 2017
Filing Date:
February 24, 2017
Export Citation:
Assignee:
ONO PHARMACEUTICAL CO (JP)
International Classes:
A61K31/4709; A61K39/395; A61K45/00; A61P35/00; A61P43/00; C07K16/18
Domestic Patent References:
| WO2015012298A1 | 2015-01-29 | |||
| WO2015012298A1 | 2015-01-29 | |||
| WO2016193680A1 | 2016-12-08 | |||
| WO2007030680A2 | 2007-03-15 | |||
| WO2007057399A2 | 2007-05-24 | |||
| WO2007070872A1 | 2007-06-21 | |||
| WO2008045978A1 | 2008-04-17 | |||
| WO2008080134A2 | 2008-07-03 | |||
| WO2008083356A1 | 2008-07-10 | |||
| WO2008128072A2 | 2008-10-23 | |||
| WO2008083353A1 | 2008-07-10 | |||
| WO2008083354A1 | 2008-07-10 | |||
| WO2008083367A2 | 2008-07-10 | |||
| WO2008083357A1 | 2008-07-10 | |||
| WO2009007390A2 | 2009-01-15 | |||
| WO2009024825A1 | 2009-02-26 | |||
| WO2009047514A1 | 2009-04-16 | |||
| WO2009053737A2 | 2009-04-30 | |||
| WO2009054864A1 | 2009-04-30 | |||
| WO2009127417A1 | 2009-10-22 | |||
| WO2010005876A2 | 2010-01-14 | |||
| WO2010005879A1 | 2010-01-14 | |||
| WO2010090764A1 | 2010-08-12 | |||
| WO2010128659A1 | 2010-11-11 | |||
| WO2012028332A1 | 2012-03-08 | |||
| WO2012135800A1 | 2012-10-04 | |||
| WO2013074633A1 | 2013-05-23 | |||
| WO2013115280A1 | 2013-08-08 | |||
| WO2013162061A1 | 2013-10-31 | |||
| WO2014091265A1 | 2014-06-19 | |||
| WO2016006706A1 | 2016-01-14 | |||
| WO2016097918A1 | 2016-06-23 |
Other References:
GRO GAUSDAL ET AL.: "Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy", CANCER IMMUNOLOGY RESEARCH, vol. 4, no. Suppl 1, January 2016 (2016-01-01), XP055519427, Retrieved from the Internet [retrieved on 20170322]
KUNIKO SUNAMI: "CTLA-4 o Hyoteki to shita Gan Men'eki Ryoho", JAPANESE JOURNAL OF CLINICAL MEDICINE (SPECIAL EXTRA ISSUE) SAISHIN GAN YAKUBUTSU RYOHOGAKU, vol. 72, 20 February 2014 (2014-02-20), pages 280 - 285
SHIN FOONG NIGLOW ET AL.: "Anti-TIM3 Antibody Promotes T Cell IFN-y-Mediated Antitumor Immunity and Suppresses Established Tumors", CANCER RESEARCH, vol. 71, no. 10, 15 May 2011 (2011-05-15), pages 3540 - 3551, XP055181433
PASERO CHRISTINE ET AL.: "Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity", IMMUNOLOGY LETTERS, vol. 151, no. 1-2, March 2013 (2013-03-01), pages 71 - 75, XP055251710
YOSHIZAWA TOSHIO ET AL.: "Abstract LB-218: Development of Axl/Mer inhibitor , ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics", CANCER RESEARCH, vol. 76, no. 14 S, July 2016 (2016-07-01), XP055537320, Retrieved from the Internet [retrieved on 20170322]
CLINICAL SCIENCE, vol. 122, 2012, pages 361 - 368
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, no. 3, 2010, pages 1124 - 1129
BLOOD, vol. 121, 2013, pages 2064 - 2073
NATURE REVIEWS CANCER, vol. 14, 2014, pages 769 - 785
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Medicaments", pages: 163 - 198
NATURE REVIEWS CANCER, vol. 12, pages 252 - 264,2012
CANCER CELL, vol. 27, 2015, pages 450 - 461
KUNIKO SUNAMI: "CTLA-4 o Hyoteki to shita Gan Men'eki Ryoho", JAPANESE JOURNAL OF CLINICAL MEDICINE (SPECIAL EXTRA ISSUE) SAISHIN GAN YAKUBUTSU RYOHOGAKU, vol. 72, 20 February 2014 (2014-02-20), pages 280 - 285
SHIN FOONG NIGLOW ET AL.: "Anti-TIM3 Antibody Promotes T Cell IFN-y-Mediated Antitumor Immunity and Suppresses Established Tumors", CANCER RESEARCH, vol. 71, no. 10, 15 May 2011 (2011-05-15), pages 3540 - 3551, XP055181433
PASERO CHRISTINE ET AL.: "Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity", IMMUNOLOGY LETTERS, vol. 151, no. 1-2, March 2013 (2013-03-01), pages 71 - 75, XP055251710
YOSHIZAWA TOSHIO ET AL.: "Abstract LB-218: Development of Axl/Mer inhibitor , ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics", CANCER RESEARCH, vol. 76, no. 14 S, July 2016 (2016-07-01), XP055537320, Retrieved from the Internet
CLINICAL SCIENCE, vol. 122, 2012, pages 361 - 368
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, no. 3, 2010, pages 1124 - 1129
BLOOD, vol. 121, 2013, pages 2064 - 2073
NATURE REVIEWS CANCER, vol. 14, 2014, pages 769 - 785
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Medicaments", pages: 163 - 198
NATURE REVIEWS CANCER, vol. 12, pages 252 - 264,2012
CANCER CELL, vol. 27, 2015, pages 450 - 461
Attorney, Agent or Firm:
AOKI, Atsushi et al. (JP)
Download PDF: